Protagonist Therapeutics, Inc. (NASDAQ: PTGX) recently disclosed that its Chief Development Officer, Suneel Gupta, sold a significant portion of the company's stock. According to a recent filing, ...

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the ...

NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its ...

NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide ...

NEWARK, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-477, a potential best-in-class GLP-1, GIP, ...

Protagonist Therapeutics (PTGX) announced the selection of PN-881, an oral peptide interleukin-17, or IL-17, antagonist, as a development candidate for the treatment of immune-mediated skin diseases.

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below The webcast link for the event can be found here: https://viavid ...